Androgenetic alopecia (AGA) — the most common form of hair loss, characterized by androgen-mediated progressive miniaturization of hair follicles in genetically susceptible individuals — affects approximately 50 million men and 30 million women in the United States, with lifetime prevalence of 80% in men and 50% in women. The treatment landscape in 2025 offers more evidence-based options than any previous era: FDA-approved topical and oral minoxidil, finasteride and dutasteride, JAK inhibitors for alopecia areata, PRP (platelet-rich plasma) injection, low-level laser therapy, and 5-ARI microneedling combinations are supported by varying levels of clinical evidence that practitioners can use to build individualized treatment plans.
Minoxidil: The Foundational Treatment
Topical minoxidil (2% for women, 5% for men; both genders by current labeling) — FDA-approved since 1988 — remains a cornerstone of AGA treatment. Mechanism: minoxidil is a potassium channel opener that prolongs the anagen (growth) phase, increases follicle size and blood flow, and may have direct anti-apoptotic effects on follicular stem cells. Efficacy data: vertex scalp hair count increases of 15–25% from baseline at 48 weeks in phase 3 trials; visual global improvement in approximately 60% of users. Oral minoxidil (0.25–1mg/day for women, 2.5–5mg/day for men) — off-label but widely used — achieves superior hair regrowth to topical in several head-to-head studies, at doses below those used for hypertension, with primary side effects of periorbital edema (5%) and hypertrichosis at higher doses (unwanted facial/body hair). A 2022 JAAD meta-analysis found oral minoxidil significantly superior to topical for AGA with an acceptable safety profile at low doses.
Finasteride and Dutasteride
Finasteride 1mg/day (Propecia, FDA-approved for male AGA) inhibits 5-alpha-reductase type II, reducing scalp DHT by approximately 60% — directly targeting the primary androgen mediating follicular miniaturization. Phase 3 data: 5-year finasteride use increased vertex hair count by 277 hairs/cm² versus placebo-treated decline; 85% of finasteride users maintained or improved versus 28% in placebo. Sexual side effects (decreased libido, erectile dysfunction) occur in approximately 2% — resolving in most cases with discontinuation, though post-finasteride syndrome (persistent sexual and neurological side effects) is the subject of ongoing investigation. Dutasteride 0.5mg (inhibits type I and II 5-ARI, reducing DHT by 90%) shows superior efficacy to finasteride in multiple head-to-head trials — a clinically meaningful advantage for patients failing finasteride. Both require 6–12 months for visible response.
PRP and Microneedling
PRP (platelet-rich plasma) — patient's own growth factor-concentrated plasma injected into the scalp — has 20+ RCTs showing significant hair density improvement versus saline control, with effect sizes of 30–40% hair count improvement. The evidence quality remains limited by small sample sizes, varied PRP preparation protocols, and absent standardization; nevertheless, PRP is increasingly incorporated into AGA treatment plans as an adjunct to pharmacological therapy, particularly in patients with incomplete response to minoxidil/finasteride. Microneedling creates microchannels enhancing minoxidil penetration (2–3× increase in absorption) and independently stimulates growth factors (VEGF, PDGF) through wounding response. Dermaroller studies show significant hair density improvement as monotherapy and additive benefit when combined with topical minoxidil. Our skin care catalog includes post-procedure scalp care products for practices offering hair restoration services.
